Company: IMNN
Filing Date: 2025-05-19
Form Type: S-1/A
Source: 0001641172-25-011388
Chunk: 15

Company: Imunon, Inc.
Filing Date: 2025-05-19
Form: S-1/A
Chunk 15
---
 
 will be decreased on a one-for-one basis. This prospectus also relates to the offering of the shares of Common Stock issuable upon          
 exercise of the pre-funded warrants. For more information regarding the pre-funded warrants, you should carefully read the section titled   
 “Description of Securities We Are Offering” in this prospectus.                                                                             |
| Common                                     
 warrants offered by us in this offering    |     | We                                                                                                                                          
 are issuing to purchasers of shares of our Common Stock and/or pre-funded warrants in this offering a common warrant to purchase one        
 share of our Common Stock for each share and/or pre-funded warrant purchased in this offering. The shares of Common Stock or                
 pre-funded warrants, respectively, and common warrants are immediately separable and will be issued separately in this offering, but        
 must initially be purchased together in this offering. The common warrants are exercisable beginning                                        
 on the Initial Exercise Date, have an assumed exercise price equal to $0.96 (equal to 200% of the assumed combined                          
 public offering price per share of Common Stock and accompanying common warrant), and will expire two and one-half (2.5) years after        
 the Initial Exercise Date. Holders of the common warrants may effect a “zero exercise price” exercise at                                    
 any time while the common warrants are outstanding following the Initial Exercise Date. Under the zero exercise price                       
 option, a holder of a common warrant has the right to receive an aggregate number of shares of Common Stock equal to the product of         
 (i) the aggregate number of shares of Common Stock that would be issuable upon a cash rather than a cashless exercise of the common         
 warrant and (ii) 3.0. The number of shares issuable on the exercise of the common warrants under the zero exercise price                    
 provision increases as the stock price declines. Accordingly, it is highly unlikely that a holder of the common warrants would              
 wish to pay an exercise price in cash to receive one share of Common Stock when they could instead choose the zero exercise price           
 option and pay no cash to receive three shares of Common Stock. As a result, we will likely not receive any additional funds and do         
 not expect to receive any additional funds upon the exercise of the common warrants. In addition, on the Adjustment Date, the               
 exercise price of the common warrants will be reduced to the greater of the Floor Price and the lowest daily dollar volume-weighted         
 average price during the period beginning two full trading days prior to the Adjustment Date and ending on the 10th trading day             
 after